<DOC>
	<DOCNO>NCT02402530</DOCNO>
	<brief_summary>This clinical trial conduct demonstrate efficacy neridronic acid treatment pain associate complex regional pain syndrome type I ( CRPS-I ) . The trial divide 3 period : 60-day enrollment period , 12-week trial period , extend follow-up period visit Month 6 , Month 9 , Month 12 . The extended follow-up period terminate participant last participant enrol completes Month 6 visit ( Visit 9 ) . The double-blind maintain throughout 12-week trial period extend follow-up period .</brief_summary>
	<brief_title>Efficacy Safety Intravenous Neridronic Acid CRPS-I</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Complex Regional Pain Syndromes</mesh_term>
	<mesh_term>Reflex Sympathetic Dystrophy</mesh_term>
	<mesh_term>Diphosphonates</mesh_term>
	<criteria>Informed consent sign . Male female participant 18 year 80 year age . A diagnosis complex regional pain syndrome type I accord clinical diagnostic criterion use International Association Study Pain clinical diagnostic criterion ( Budapest criterion ) . Baseline Pain Intensity Score 4 great use 11point Numerical Rating Scale refer CRPSaffected limb . In stable treatment followup therapy CRPS type I least 1 month . Participant undergone recent regular dental examination . Women childbearing potential must negative urine ÃŸHCG pregnancy test enrollment . Women childbearing potential must practice protocol define acceptable method birth control trial . Participants must able communicate meaningfully , able differentiate regard location intensity pain , able answer question questionnaire use trial . Compliance use electronic diary assess prior allocation treatment . A diagnosis complex regional pain syndrome type II . Documented history diagnosis peripheral neuropathy , include diabetic peripheral neuropathy metabolic toxic neuropathy , chronic pain condition would significantly affect participant 's ability report CRPSrelated pain . Body weight less 40 kg . Evidence renal impairment history chronic kidney disease . Serum calcium magnesium outside central laboratory 's reference range ; history hypocalcemia ; metabolic disorder anticipate increase risk hypocalcemia . Vitamin D deficiency . Participants vitamin D deficiency prior enrollment may enrol appropriate supplementation enrollment period . Corrected QT interval great 470 millisecond ; treatment medication within last 30 day prior allocation IMP potential prolong QT interval anticipate need medication course trial . Any prior use bisphosphonate treatment CRPS , prior administration intravenous bisphosphonate , administration oral bisphosphonate within previous year , anticipated requirement treatment oral intravenous bisphosphonate another condition osteoporosis trial , administration denosumab ( Prolia ) bone turnover suppress drug within past 6 month . History allergic hypersensitivity reaction neridronic acid bisphosphonate , vitamin D calcium supplement . Recent tooth extraction , unhealed infect extraction site , significant dental/periodontal disease may predispose need tooth extraction invasive dental procedure trial . Evidence denturerelated gum trauma improperly fit denture cause injury . Prior radiation therapy head neck ( within 1 year enrollment ) . Recent treatment high dos systemic steroid anticipate need concomitant highdose steroid treatment trial . History malignancy within 2 year enrollment exception basal cell carcinoma . Daily intake long shortacting controlledrelease opioid analgesic 200 mg morphine equivalent , regimen combine highdose opioids benzodiazepine , treatment regimen consider unstable , unsafe , potential affect interpretation trial . Use nerve block , ketamine infusion , intravenous immunoglobulin , acupuncture , electromagnetic field treatment , initiation/implementation radiofrequency ablation sympathectomy procedure , peripheral nerve stimulation within 6 week prior allocation investigational medicinal product . Evidence current alcohol drug abuse , history alcohol drug abuse within 2 year enrollment , base participant history physical examination accord investigator 's judgment . Any severe medical condition , include severe depression , severe mood disorder , opinion investigator may affect efficacy safety assessment may compromise participant 's safety trial participation . Participant engage litigation relate disability CRPS monetary gain loss ( compensation ) may affect objective participation trial . Women pregnant breastfeeding . Elevated aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) great 2fold upper limit normal ( ULN ) , evidence history liver disease . Participation investigational drug trial within 3 month prior enrollment , prior participation trial receipt infusion IMP , even partial infusion .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Neridronic Acid</keyword>
	<keyword>Neridronate</keyword>
	<keyword>CRPS</keyword>
	<keyword>RSD</keyword>
</DOC>